INGIBIROVANIE BIOSINTEZA KhOLESTERINA KAK TARGETNAYa TERAPIYa PRI SHH-OPOSREDOVANNYKh ONKOLOGIChESKIKh ZABOLEVANIYaKh

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription or Fee Access

Rubin L. L., de Sauvage F. J. Targeting the Hedgehog pathway in cancer // Nature Reviews Drug Discovery.- 2006.- Vol. 12.- P. 1026-1033.
Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma / Packer R. J., Gajjar A. J., Vezina G., Rorke-Adams L., Burger P. C., Robertson P. L. et al. // Journal of Clinical Oncology.- 2006.- Vol. 24.- P. 4202-4208.
Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells / Yang Z. J., Ellis T., Markant S. L., Read T. A., Kessler J. D., Bourboulas M., et al. // Cancer Cell.- 2008.- Vol. 14.- P. 135-145.
Subtypes of medulloblastoma have distinct developmental origins / Gibson P., Yong T., Robinson G., Thompson M. C., Currle D. S., Eden C., et al. // Nature.- 2010.- Vol. 468.- P. 1095-1099.
Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma / Mulhern R. K., Palmer S. L., Merchant T. E., Wallace D., Kocak M., Brouwers P., et al. // Journal of Clinical Oncology.- 2005.- Vol. 24.- P. 5511-5519.
Hedgehog pathway modulation by multiple lipid binding sites on the smoothened effector of signal response / Myers В. R., Sever N., Chong Y. C., Kim J., Belani J. D., Ruchnovsky S., et al. // Developmental Cell.- 2013.- Vol. 26 - P. 347-356.

Supplementary Files

Action

1. JATS XML